通过p53信号通路靶向B细胞淋巴瘤细胞的高选择性口服生物利用度酪蛋白激酶1α降解剂
研究开发了CRBN依赖性CK1α降解剂INNO-220,其高选择性降解CK1α而不影响IKZF1/3。在淋巴瘤细胞系中,携带野生型p53且NF-κB信号组成性激活的细胞对CK1α降解敏感但对BTK抑制剂耐药。INNO-220抑制NF-κB信号并激活p53通路,在体内完全抑制淋巴瘤肿瘤生长。
要点
- INNO-220是高选择性口服CK1α降解剂,不影响IKZF1/3。
- 野生型p53且NF-κB组成性激活的淋巴瘤细胞对INNO-220敏感。
- INNO-220破坏CARD11/BCL10/MALT1复合物组装并激活p53。
核心结论
- INNO-220作为一种选择性CK1α降解剂,为淋巴瘤治疗提供了新策略,并提供了机制见解和潜在的患者选择策略。
研究设计与样本
- 研究利用T细胞中的细胞因子表达谱分析开发了CRBN依赖性CK1α降解剂INNO-220,并在淋巴瘤细胞系中进行了筛选。
- 研究在体内评估了INNO-220对淋巴瘤肿瘤生长的影响。
主要发现
- 与来那度胺不同,INNO-220是高选择性且强效的CK1α降解剂,不影响IKZF1/3。
- 在淋巴瘤细胞系筛选中,携带野生型p53且NF-κB信号组成性激活的细胞对CK1α降解敏感,但对Bruton酪氨酸激酶抑制剂耐药。
- INNO-220抑制NF-κB信号并激活p53通路,在体内完全抑制淋巴瘤肿瘤生长。
- INNO-220破坏CARD11/BCL10/MALT1复合物的组装和功能,从而抑制刺激T细胞和携带CARD11激活突变的淋巴瘤细胞中的NF-κB信号。
- INNO-220处理激活野生型p53足以诱导强效癌细胞死亡,即使在没有NF-κB组成性活性时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The modest reduction in casein kinase 1 alpha (CK1α) by lenalidomide contributes to its clinical effectiveness in treating del(5q) myelodysplastic syndrome. However, the mechanism by which CK1α impacts lymphoma survival remains inadequately defined. We developed INNO-220, a CRBN-dependent CK1α degrader, by leveraging cytokine expression profiling in T cells. Unlike lenalidomide, INNO-220 is a highly selective and potent degrader of CK1α without affecting IKZF1/3. Screening across lymphoma cell lines revealed that cells harboring wild-type p53 and exhibiting constitutive NF-κB signaling were particularly sensitive to CK1α degradation yet resistant to Bruton tyrosine kinase inhibitors. Moreover, INNO-220 suppresses NF-κB signaling and activates p53 pathway, leading to complete inhibition of lymphoma tumor growth in vivo. Mechanistically, INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, thereby inhibiting NF-κB signaling in stimulated T cells and lymphoma cells that harbor an activating mutation in CARD11. Moreover, we observed that activation of wild-type p53 upon INNO-220 treatment was sufficient to induce potent cancer cell death even in the absence of constitutive NF-κB activity. In summary, our findings introduce a selective CK1α degrader as a novel therapeutic approach for lymphoma, providing both mechanistic insights and a potential patient selection strategy in treating lymphoma and possibly other cancers.
引用
- Feng S, Kong R, Wang C, et al. A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells. Leukemia. 2025. PMID: 40425803. doi:10.1038/s41375-025-02647-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。